Olmesartan medoxomil is an angiotensin II receptor blocker approved by the FDA for the treatment of high blood pressure. It is marketed as Benicar, Benicar HCT, Azor, and Tribenzor. On July 14, 2015, the Supreme Court designated all pending and future litigation involving alleged personal injuries of sprue-like enteropathy and/or lymphocytic colitis, microscopic colitis or collagenous colitis, and other symptoms as a result of treatment with medications containing olmesartan medoxomil as multicounty litigation and assigned it for centralized management in Atlantic County.